Announcement PDF patrys.com ASX: PAB Investor Presentation Update 1 March 2026 Patrys Limited (ASX:PAB) Disclaimer The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capital invested and no return of income or payment of dividends. Neither Patrys nor any other entity or person in or associated with the Patrys group of companies guarantees any return (whether capital or income) or generally the performance of Patrys or the price at which its securities may trade. In particular, this presentation is not a recommendation, offer or invitation to subscribe for or purchase Patrys securities. It is not for general distribution or third party reliance or use. While it has been prepared from sources Patrys believe to be reliable, Patrys cannot guarantee its accuracy or completeness and undertakes no obligation to advise of changes or updates to any such materials. These materials are not exhaustive of all of the information a potential investor or their professional adviser would require. Nor do these materials take into account any specific objectives, financial situation or needs of investors. In addition, the past performance of Patrys cannot be assumed as indicative of the future performance of the company. For these and other reasons, before making any investment decision regarding Patrys securities you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk. Where this presentation does contain any forward looking statements, those statements are only made as the date of the presentation and are to be considered “at-risk statements” not to be relied upon as they are subject to further research and to known and unknown risks, uncertainties and other factors that may lead to actual results differing from any forward looking statement. This is particularly the case with companies such as Patrys which operate in the field of researching, discovering, developing, and commercialising potential drugs intended for safe and effective for human treatments or therapies. 2 Patrys Limited (ASX:PAB) A Faster, Lower-Risk Path to a >US$2B Delirium Market Reformulating a proven drug to deliver a faster, lower-risk path to market Proven Drug Reformulated for ICU Accelerated Development Pathway  Quetiapine already widely used in clinical practice  Safety and efficacy well understood  Extensive human clinical data available  New proprietary Injectable formulation with patent protection extending to ~20421  Immediate onset vs oral dosing  Suitable for ICU, palliative and aged care settings  FDA 505(b)(2) regulatory pathway  3–5 year development timeline  ~$20–30M development cost vs ~$1.2B for new drugs Traditional Biotech Patrys Reformulation New molecule discovery Known drug reformulated 10–15 years 3–5 years ~$1.2B ~$20–30M 3 Patrys Limited (ASX:PAB) Board of Directors Peter Christie CHAIRMAN • 25+ years ASX governance and board experience • Chairman of multiple ASX- listed companies Leanne Kite DIRECTOR • Capital markets, finance and investor relations executive with 20+ years’ experience • Heads investor relations for ASX 200 lithium producer Liontown Resources Dino Cercarelli DIRECTOR • Clinical trial and healthcare operations leader • COO of Australian Clinical Trials Alliance Brian Leedman DIRECTOR • Biotech entrepreneur with strong ASX healthcare track record • Co-founder of ResApp Health (acquired by Pfizer) Dr Anton Uvarov DIRECTOR • Healthcare and biotech investment specialist • Former Citigroup healthcare equities analyst ASX Governance Biotech Commercialisation Capital Markets, Finance & Investor Relations Clinical Trial Operations Healthcare & Biotech Investment Board combining biotech, clinical development and capital markets expertise 4 Patrys Limited (ASX:PAB) Delirium:SevereandAcuteBrainDysfunction Delirium: Severe and Acute Brain Dysfunction Cognitive Decline Confusion Disorientation Altered Thinking & Behavious 3 Forms • Withdrawn (Hypoactive) • Mixed • Aggressive (Hyperactive) 1 Richardson et al., Age and Ageing 2021; 50: 914–920 Up to 80% of ICU patients experience delirium Increased Risk Of Dementia1 5 Patrys Limited (ASX:PAB) Estimated Serviceable Addressable Market >US$2 Billion per year Patrys Limited (ASX:PAB) The Problem: Current Treatment Challenges 6 • No approved drug treatments • Current treatments used “ OFF-LABEL” • Oral quetiapine difficult to administer to delirium patients “OFF-LABEL” Antipsychotic & Benzodiazepine • Haloperidol • Risperidone • Dexmedetomidine • Benzodiazepines • Sedatives Limitations of current “OFF-LABEL” treatments  Variable Effectiveness  Low quality data supporting use  Significant adverse side-effect profiles Quetiapine: Atypical Antipsychotic • Only available as oral formulation • Slow onset of action (1-2h) • Difficult to administer to delirium patients Oral Quetiapine demonstrated comparative Evidence of Benefit in Delirium patients and a lower side effect profile2 1.. Alghadeer et al., 2024 | 2. Devlin et al., 2010; Oztuzzi et al., 2020 40% 4% 47% 9% Haloperidol Olanzapine Quetiapine Risperidone Oral Quetiapine commonly prescribed1 Patrys Limited (ASX:PAB) Solution: Proprietary Injectable Quetiapine • Rapid control of acute agitation episodes • Faster resolution of delirium • Improved safety for patients and staff • Shorter ICU and hospital stays • Cost of care reduced 7 Patrys Limited (ASX:PAB) A Faster Path to Market Reformulation strategy enables faster, de-risked drug development 2–3× Higher success rate vs novel drugs 40–60% Lower cost & timeline 8 Patrys Limited (ASX:PAB) Risk Factor Typical Biotech Risk This Asset Investor Takeaway Market Demand & Unmet Need • Competing with approved drugs • Must displace established therapies • No approved drug • Clear unmet need in large, growing market Open market with clear demand - no incumbent to displace Intellectual Property Defence • Workarounds feasible • Weak IP • Technical complexity creates a structural barrier for workarounds • Not relying on reg exclusivity (Hatch-Waxman) Defensible IP supports premium valuation and limits competition Manufacturing & Scale-Up Risk • Unproven scale-up • Process risk • Already manufactured at commercial scale • No scale-up required Low execution risk – no scale-up required Regulatory & Reimbursement Risk • Long approval timelines • Payer resistance without clear clinical need • Accelerated reformulation pathway • Established efficacy profile supports reimbursement Clear and accelerated path to approval and reimbursement Clinical & Formulary Adoption • Uncertain reimbursement coverage • Slow adoption timelines • Designed for clinical workflow • Positioned for formulary inclusion Strong adoption potential driven by clinical need and workflow fit A Structurally De-Risked Opportunity 9 Compared to a typical biotech program, this asset is de-risked across all major value drivers HIGH HIGH HIGH HIGH MEDIUM LOW LOW LOW LOW LOW Patrys Limited (ASX:PAB) Accelerated Clinical Development Pathway Bridging Studies Required • Human micro-dosing + PBPK modelling • Predict human dose and administration • Leverages existing quetiapine safety data Extensive prior safety data reduces development risk 1.Subjects and Patient numbers are subject to Regulatory and Ethics approvals Phase 1A Clinical Trial • healthy volunteers1 • PK and safety Phase 1B Study • ICU patients1 • Safety and feasibility • First ICU efficacy data Global pivotal ICU delirium study • Global ICU delirium registrational study • Safety and efficacy Determine dose FDA pre-IND submission FDA IND submission Pre-Study Preparation • Finalise manufacturing (CMC) • CRO site setup and ethics approvals • Recruit healthy volunteers Potential partnering / licensing point 2026 H1 2026 H2 2027 2028 03 02 01 10 Patrys Limited (ASX:PAB) Clinical Development Timeline and Key Value Catalysts Event Target Date Ethics Approval for Phase 1A Q2 2026 Phase 1A trial Initiation Q3 2026 GMP clinical batch release Q4 2026 Phase 1A Completion Q4 2026 FDA pre-IND response Q4 2026 6 months DP stability for Phase 1B and CMC Q1 2027 Ethics approval Phase 1B Q1 2027 Phase 1B first patient dosed Q2 2027 Phase 1B completion Q3 2027 IND submission Q4 2027 Because we are reformulating a drug with extensive clinical history, the bridging studies focus on confirming dosing and clinical safety rather than discovery Multiple near-term clinical and regulatory milestones expected over the next 18–24 months. Extensive existing clinical data Decades of clinical use of oral quetiapine significantly reduces technical and regulatory risk for the IV reformulation program Capital efficient development pathway Key development activities are conducted ahead of and alongside Phase 1A to enable rapid progression into Phase 1B Phase 1A: Dose Confirmation Phase 1A confirms dosing and safety for the IV formulation using the established clinical profile of quetiapine Phase 1B: Safety in ICU setting Phase 1B evaluates safety of the IV formulation in a small number of ICU patients 11 Patrys Limited (ASX:PAB) Corporate Snapshot Notes: 1. Shares on issue is shown undiluted. There are convertible securities on issue as follows: a) 90.8M options on issue, exercisable at 2.4cps on or before Nov 29 b) 40M Class A Performance Rights convertible upon the first subject being dosed in a Phase 1 Clinical Study, within three years from the date of issue c) 30M Class B Performance Rights convertible upon successful IND approval by a regulatory body, within five years from the date of issue 2. Share price as at 30 Mar 26 3. Cash balance as per last public disclosure as at 31 Dec 25 Capital Structure Shares on issue 1 532,396,581 Share price 2 2.8c Market capitalisation $15M Cash 3 $1.9M Debt Nil Enterprise Value $14.5M Share Price History Market Opportunity ~US$2B Serviceable addressable delirium treatment market 12 Patrys Limited (ASX:PAB) A Faster, Lower-Risk Path to a >US$2B Delirium Market Reformulating a proven drug to deliver a faster, lower-risk path to market Proven Drug Reformulated for ICU Accelerated Development Pathway  Quetiapine already widely used in clinical practice  Safety and efficacy well understood  Extensive human clinical data available  New proprietary Injectable formulation with patent protection extending to ~20421  Immediate onset vs oral dosing  Suitable for ICU, palliative and aged care settings  FDA 505(b)(2) regulatory pathway  3–5 year development timeline  ~$20–30M development cost vs ~$1.2B for new drugs Traditional Biotech Patrys Reformulation New molecule discovery Known drug reformulated 10–15 years 3–5 years ~$1.2B ~$20–30M 13 Dr. Samantha South Phone: +61 421 117 241 Email: info@patrys.com Patrys Limited (ASX:PAB) patrys.com Contact Proven drug, better delivery. De-risked investment. Patrys Limited (ASX:PAB)